QCG
TRVI icon

Quadrant Capital Group’s Trevi Therapeutics TRVI Stock Holding History

Quadrant Capital Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-789
Closed -$9.41K – 2486
2026
Q1 		$9.41K Hold
789
– – ﹤0.01% 2204
2025
Q4 		$9.88K Hold
789
– – ﹤0.01% 2208
2025
Q3 		$7.22K Buy
+789
New +$5.92K ﹤0.01% 2247

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Quadrant Capital Group's TRVI Position: Q2 2026 in Review

Quadrant Capital Group sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 789 shares — an estimated $9.41K sold.

Quadrant Capital Group first reported a position in TRVI in Q3 2025 and held it in 3 quarters. The position peaked at $9.88K in Q4 2025. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Quadrant Capital Group reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 789 Trevi Therapeutics shares in Q2 2026, an estimated $9.41K.
  • Quadrant Capital Group first reported a position in Trevi Therapeutics in Q3 2025 and held it in 3 quarters.
  • Quadrant Capital Group's Trevi Therapeutics position peaked at $9.88K in Q4 2025.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.